Penalized landmark supermodels (penLM) for dynamic prediction for time-to-event outcomes in high-dimensional data.

IF 3.4 3区 医学 Q1 HEALTH CARE SCIENCES & SERVICES BMC Medical Research Methodology Pub Date : 2025-01-27 DOI:10.1186/s12874-024-02418-9
Anya H Fries, Eunji Choi, Summer S Han
{"title":"Penalized landmark supermodels (penLM) for dynamic prediction for time-to-event outcomes in high-dimensional data.","authors":"Anya H Fries, Eunji Choi, Summer S Han","doi":"10.1186/s12874-024-02418-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To effectively monitor long-term outcomes among cancer patients, it is critical to accurately assess patients' dynamic prognosis, which often involves utilizing multiple data sources (e.g., tumor registries, treatment histories, and patient-reported outcomes). However, challenges arise in selecting features to predict patient outcomes from high-dimensional data, aligning longitudinal measurements from multiple sources, and evaluating dynamic model performance.</p><p><strong>Methods: </strong>We provide a framework for dynamic risk prediction using the penalized landmark supermodel (penLM) and develop novel metrics ([Formula: see text] and [Formula: see text]) to evaluate and summarize model performance across different timepoints. Through simulations, we assess the coverage of the proposed metrics' confidence intervals under various scenarios. We applied penLM to predict the updated 5-year risk of lung cancer mortality at diagnosis and for subsequent years by combining data from SEER registries (2007-2018), Medicare claims (2007-2018), Medicare Health Outcome Survey (2006-2018), and U.S. Census (1990-2010).</p><p><strong>Results: </strong>The simulations confirmed valid coverage (~ 95%) of the confidence intervals of the proposed summary metrics. Of 4,670 lung cancer patients, 41.5% died from lung cancer. Using penLM, the key features to predict lung cancer mortality included long-term lung cancer treatments, minority races, regions with low education attainment or racial segregation, and various patient-reported outcomes beyond cancer staging and tumor characteristics. When evaluated using the proposed metrics, the penLM model developed using multi-source data ([Formula: see text]of 0.77 [95% confidence interval: 0.74-0.79]) outperformed those developed using single-source data ([Formula: see text]range: 0.50-0.74).</p><p><strong>Conclusions: </strong>The proposed penLM framework with novel evaluation metrics offers effective dynamic risk prediction when leveraging high-dimensional multi-source longitudinal data.</p>","PeriodicalId":9114,"journal":{"name":"BMC Medical Research Methodology","volume":"25 1","pages":"22"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771018/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Research Methodology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12874-024-02418-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To effectively monitor long-term outcomes among cancer patients, it is critical to accurately assess patients' dynamic prognosis, which often involves utilizing multiple data sources (e.g., tumor registries, treatment histories, and patient-reported outcomes). However, challenges arise in selecting features to predict patient outcomes from high-dimensional data, aligning longitudinal measurements from multiple sources, and evaluating dynamic model performance.

Methods: We provide a framework for dynamic risk prediction using the penalized landmark supermodel (penLM) and develop novel metrics ([Formula: see text] and [Formula: see text]) to evaluate and summarize model performance across different timepoints. Through simulations, we assess the coverage of the proposed metrics' confidence intervals under various scenarios. We applied penLM to predict the updated 5-year risk of lung cancer mortality at diagnosis and for subsequent years by combining data from SEER registries (2007-2018), Medicare claims (2007-2018), Medicare Health Outcome Survey (2006-2018), and U.S. Census (1990-2010).

Results: The simulations confirmed valid coverage (~ 95%) of the confidence intervals of the proposed summary metrics. Of 4,670 lung cancer patients, 41.5% died from lung cancer. Using penLM, the key features to predict lung cancer mortality included long-term lung cancer treatments, minority races, regions with low education attainment or racial segregation, and various patient-reported outcomes beyond cancer staging and tumor characteristics. When evaluated using the proposed metrics, the penLM model developed using multi-source data ([Formula: see text]of 0.77 [95% confidence interval: 0.74-0.79]) outperformed those developed using single-source data ([Formula: see text]range: 0.50-0.74).

Conclusions: The proposed penLM framework with novel evaluation metrics offers effective dynamic risk prediction when leveraging high-dimensional multi-source longitudinal data.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
惩罚地标超模(penLM)在高维数据中对事件时间结果的动态预测。
背景:为了有效监测癌症患者的长期预后,准确评估患者的动态预后是至关重要的,这通常涉及使用多个数据源(例如,肿瘤登记、治疗史和患者报告的结果)。然而,在从高维数据中选择特征来预测患者预后、对齐来自多个来源的纵向测量以及评估动态模型性能方面存在挑战。方法:我们提供了一个使用受惩罚地标超级模型(penLM)进行动态风险预测的框架,并开发了新的指标([公式:见文本]和[公式:见文本])来评估和总结模型在不同时间点的性能。通过模拟,我们评估了在各种情况下所提出的度量的置信区间的覆盖率。我们将SEER登记(2007-2018年)、医疗保险索赔(2007-2018年)、医疗保险健康结局调查(2006-2018年)和美国人口普查(1990-2010年)的数据结合起来,应用penLM预测诊断时和随后几年肺癌死亡的最新5年风险。结果:模拟证实了所提出的汇总指标置信区间的有效覆盖率(~ 95%)。4670名肺癌患者中,41.5%死于肺癌。使用penLM,预测肺癌死亡率的关键特征包括长期肺癌治疗、少数民族、受教育程度低的地区或种族隔离,以及癌症分期和肿瘤特征之外的各种患者报告的结果。当使用提出的指标进行评估时,使用多源数据([公式:见文本]0.77[95%置信区间:0.74-0.79])开发的penLM模型优于使用单源数据([公式:见文本]范围:0.50-0.74)开发的penLM模型。结论:提出的penLM框架具有新颖的评估指标,在利用高维多源纵向数据时,可以有效地进行动态风险预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Medical Research Methodology
BMC Medical Research Methodology 医学-卫生保健
CiteScore
6.50
自引率
2.50%
发文量
298
审稿时长
3-8 weeks
期刊介绍: BMC Medical Research Methodology is an open access journal publishing original peer-reviewed research articles in methodological approaches to healthcare research. Articles on the methodology of epidemiological research, clinical trials and meta-analysis/systematic review are particularly encouraged, as are empirical studies of the associations between choice of methodology and study outcomes. BMC Medical Research Methodology does not aim to publish articles describing scientific methods or techniques: these should be directed to the BMC journal covering the relevant biomedical subject area.
期刊最新文献
Reporting of dog-assisted intervention trials: extension of the SPIRIT 2025 and CONSORT 2025 statement. A systematic review of sample size determination in Bayesian randomized clinical trials: full Bayesian methods are rarely used. AI-derived constrained conditional model for screening marker genes through integrated high-throughput transcriptome big data. A causal inference framework for poststratification: a method for improving external validity in epidemiological studies. Lessons learned from a door-to-door screening program for developmental delay and motor impairment in children in Cuenca, Ecuador.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1